Novel psoriasis therapies and patient outcomes, part 2: biologic treatments

Biologic treatments have revolutionized the management of psoriasis and psoriatic arthritis (PsA). Anti-tumor necrosis factor (TNF) α monoclonal antibodies presently are approved by the US Food and Drug Administration (FDA) for treatment of these conditions. In this article, new therapies that targe...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cutis (New York, N.Y.) N.Y.), 2015-05, Vol.95 (5), p.282-290
Hauptverfasser:	Feely, Meghan A, Smith, Barry L, Weinberg, Jeffrey M
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Arthritis, Psoriatic - drug therapy Arthritis, Psoriatic - pathology Drug Approval Humans Immunologic Factors - pharmacology Immunologic Factors - therapeutic use Psoriasis - drug therapy Psoriasis - pathology Tumor Necrosis Factor-alpha - antagonists & inhibitors United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!